SELLAS Life Sciences prices $20M public offering of common stock and warrants

SELLAS Life Sciences Group, Inc.

7,220,217 shares and warrants at $2.77/unit; gross proceeds $20M.
Net proceeds ~$18.5M after underwriting discounts and offering expenses.
Warrants exercisable at $2.77/share, immediately exercisable, expire in 5 years.
Company reduces exercise price of 3,438,851 existing warrants to $3.62.
Offering expected to close on February 28, 2023, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $18.5 million (effective 2023-02-23).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co.
Value: approximately $18.5 million
Effective: 2023-02-23

Exact text from the filing

On February 23, 2023, SELLAS Life Sciences Group, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Cantor Fitzgerald & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 7,220,217 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and warrants (the “ Warrants ”, and together with the Underwritten Shares, the “ Securities ”) to purchase up to 7,220,217 shares of Common Stock.

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-025048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.